Allergan PLC.

AGN-N

Analysis and Opinions about AGN-N

Signal
Opinion
Expert
COMMENT
COMMENT
July 17, 2019
The aesthetics business of this Botox maker account for over 40% of company revenues and this the top player in the business. They also have clinical drugs for application like urinary, psychiatric and migraines.
Show full opinionHide full opinion
Allergan PLC. (AGN-N)
July 17, 2019
The aesthetics business of this Botox maker account for over 40% of company revenues and this the top player in the business. They also have clinical drugs for application like urinary, psychiatric and migraines.
HOLD
HOLD
May 3, 2019
Hold onto this stock. Even though the balance sheet is not great, there is a good chance their aggressive earnings outlook will drag the stock back up. It is extremely cheap at these levels.
Show full opinionHide full opinion
Hold onto this stock. Even though the balance sheet is not great, there is a good chance their aggressive earnings outlook will drag the stock back up. It is extremely cheap at these levels.
PAST TOP PICK
PAST TOP PICK
January 17, 2019
(A Top Pick Dec 15/18, Down 8%) He sold in the $1.90 range. There is talk of them spinning out their cosmetic division but it has not happened yet. He could get back into it. He was unfortunate trading this.
Show full opinionHide full opinion
Allergan PLC. (AGN-N)
January 17, 2019
(A Top Pick Dec 15/18, Down 8%) He sold in the $1.90 range. There is talk of them spinning out their cosmetic division but it has not happened yet. He could get back into it. He was unfortunate trading this.
PAST TOP PICK
PAST TOP PICK
July 5, 2018

(A Top Pick September 14/17- Down 22%.) This was a high-risk position. They sold a drug to a native band and then they leased the rights back to circumvent potential generic competition. Something cheeky and probably that is why the stock sold off. Their strength is still in Botox and aesthetics. He doesn’t see that changing or being threat. He still likes it. Management is under the gun.

Show full opinionHide full opinion

(A Top Pick September 14/17- Down 22%.) This was a high-risk position. They sold a drug to a native band and then they leased the rights back to circumvent potential generic competition. Something cheeky and probably that is why the stock sold off. Their strength is still in Botox and aesthetics. He doesn’t see that changing or being threat. He still likes it. Management is under the gun.

DON'T BUY
DON'T BUY
May 24, 2018

Form a valuation standpoint, trading at 10 times forward earnings with high single digit growth rate. But the stock keeps falling down. He would be very careful with this. Could be a value trap.

Show full opinionHide full opinion

Form a valuation standpoint, trading at 10 times forward earnings with high single digit growth rate. But the stock keeps falling down. He would be very careful with this. Could be a value trap.

TOP PICK
TOP PICK
December 14, 2017

They are the maker of Botox. They have a drug for dry eye syndrome that will come off patent but his analysis of the case for losing all revenue from the drug has them still doing well. They have a good drug pipeline. (Analysts’ target: $225.00).

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
December 14, 2017

They are the maker of Botox. They have a drug for dry eye syndrome that will come off patent but his analysis of the case for losing all revenue from the drug has them still doing well. They have a good drug pipeline. (Analysts’ target: $225.00).

SELL
SELL
December 7, 2017

Their number 1 product is Botox and their number 2 product is eye drops, and there is some competition coming from generics for their eyedrops drug. Thinks that is what has been hurting the stock recently. When the technicals are working against you where a stock has fallen below the 200-day moving average, and the price is below both the 50 day and 100 day, technically you want to step away.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
December 7, 2017

Their number 1 product is Botox and their number 2 product is eye drops, and there is some competition coming from generics for their eyedrops drug. Thinks that is what has been hurting the stock recently. When the technicals are working against you where a stock has fallen below the 200-day moving average, and the price is below both the 50 day and 100 day, technically you want to step away.

SELL
SELL
October 18, 2017

(Market Call Minute.) A broken stock and he would Sell it and move on.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
October 18, 2017

(Market Call Minute.) A broken stock and he would Sell it and move on.

DON'T BUY
DON'T BUY
September 21, 2017

We are in a structural bull market for equities. We are skating through the two toughest months of the year without much volatility. Don’t buy a company that has been put into the penalty box. Stocks that have broken down have an army of people who just want to get their money back.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
September 21, 2017

We are in a structural bull market for equities. We are skating through the two toughest months of the year without much volatility. Don’t buy a company that has been put into the penalty box. Stocks that have broken down have an army of people who just want to get their money back.

TOP PICK
TOP PICK
September 14, 2017

They are known for Botox. Aesthetics is a big part of their business as well as a great urology business and Gastro Intestinal business. They sold their urology business and reinvested their cash into R&D. It is very inexpensive. (Analysts’ target: $271.50).

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
September 14, 2017

They are known for Botox. Aesthetics is a big part of their business as well as a great urology business and Gastro Intestinal business. They sold their urology business and reinvested their cash into R&D. It is very inexpensive. (Analysts’ target: $271.50).

COMMENT
COMMENT
May 10, 2017

This has things like Botox, etc., but also have some things on the pharmaceutical side. He felt that they had a great quarter. Made 10 acquisitions in the past year with the proceeds of the generics they sold to Teva. Trading around 13X forward earnings, so not terribly expensive. He likes this one.

Show full opinionHide full opinion

This has things like Botox, etc., but also have some things on the pharmaceutical side. He felt that they had a great quarter. Made 10 acquisitions in the past year with the proceeds of the generics they sold to Teva. Trading around 13X forward earnings, so not terribly expensive. He likes this one.

COMMENT
COMMENT
March 13, 2017

He likes the pharmaceuticals. They are under a bit of pressure from legislation on repricing, but thinks most of that is priced in. He would say “yes” for this one.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
March 13, 2017

He likes the pharmaceuticals. They are under a bit of pressure from legislation on repricing, but thinks most of that is priced in. He would say “yes” for this one.

Matt Kacur

Unlock Ratings

Price
$240.650
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
February 9, 2017

(Top Pick Nov 29/16, Up 28.87%) He still likes it despite the return. They are very diligent at returning to shareholders. They have been making strategic acquisitions and their pipeline is full. He continues to like it.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
February 9, 2017

(Top Pick Nov 29/16, Up 28.87%) He still likes it despite the return. They are very diligent at returning to shareholders. They have been making strategic acquisitions and their pipeline is full. He continues to like it.

PAST TOP PICK
PAST TOP PICK
January 10, 2017

(A Top Pick Aug 17/16. Down 13.44%.) A terrific company, and shows up as the highest quality company in its group. Unfortunately, they got painted by the specialty pharmaceutical brush. It is getting a bit of a reprieve right now. He still likes this. It has one of the best growth profiles of any of the specialty pharmaceutical companies. The majority of its businesses are not subject to the same type of price controls that could come under government scrutiny.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
January 10, 2017

(A Top Pick Aug 17/16. Down 13.44%.) A terrific company, and shows up as the highest quality company in its group. Unfortunately, they got painted by the specialty pharmaceutical brush. It is getting a bit of a reprieve right now. He still likes this. It has one of the best growth profiles of any of the specialty pharmaceutical companies. The majority of its businesses are not subject to the same type of price controls that could come under government scrutiny.

COMMENT
COMMENT
November 30, 2016

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Of the 2, this is a much larger company and more broadly-based.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
November 30, 2016

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Of the 2, this is a much larger company and more broadly-based.

Gordon Reid

Unlock Ratings

Price
$194.300
Owned
Unknown
TOP PICK
TOP PICK
November 29, 2016

The healthcare sector has been the worst sector of the S&P 500 year-to-date, and yet the long-term fundamentals are still very strong. You have a growing global population and an aging population. That means the healthcare system, from a utilization standpoint, is going to continue to be under a lot of pressure regardless of Obama care. The valuation on the healthcare sector in general has not been this low since 2009 and back in 1994 for the past 25 years. They recently sold their generic business to Teva (TEVA-N) and got $40 billion. They are using the cash to buy back debt and to buy back stock. This owns Botox, one of the largest consumer drugs in the world. They are using the cash they got, to make small acquisitions to bolster their drug pipeline. Dividend yield of 1.44%. (Analysts’ price target is $266.11.)

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
November 29, 2016

The healthcare sector has been the worst sector of the S&P 500 year-to-date, and yet the long-term fundamentals are still very strong. You have a growing global population and an aging population. That means the healthcare system, from a utilization standpoint, is going to continue to be under a lot of pressure regardless of Obama care. The valuation on the healthcare sector in general has not been this low since 2009 and back in 1994 for the past 25 years. They recently sold their generic business to Teva (TEVA-N) and got $40 billion. They are using the cash to buy back debt and to buy back stock. This owns Botox, one of the largest consumer drugs in the world. They are using the cash they got, to make small acquisitions to bolster their drug pipeline. Dividend yield of 1.44%. (Analysts’ price target is $266.11.)

PAST TOP PICK
PAST TOP PICK
November 21, 2016

(Top Pick Dec 10/15, Down 37.63%) Everyone got blindsided when the US government stopped the deal with PFE-N. But look at the M&A that has started since the election. He scaled the position back a bit

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
November 21, 2016

(Top Pick Dec 10/15, Down 37.63%) Everyone got blindsided when the US government stopped the deal with PFE-N. But look at the M&A that has started since the election. He scaled the position back a bit

BUY
BUY
October 11, 2016

Very well-managed company. They have some very good in-line products and have been building up the sales force. Has a nice, promotionally responsive product portfolio and are adding salesforce to that, which is typically a good equation. The one risk was the Actavis (ACTA-Q) component, but once they became a part of this company, their behaviour calmed down.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
October 11, 2016

Very well-managed company. They have some very good in-line products and have been building up the sales force. Has a nice, promotionally responsive product portfolio and are adding salesforce to that, which is typically a good equation. The one risk was the Actavis (ACTA-Q) component, but once they became a part of this company, their behaviour calmed down.

HOLD
HOLD
August 31, 2016

On some of the pharmaceuticals we consistently see some strong volatility, particularly if they lose a trial or their main drugs become generic. Rather than looking at some of these pharmaceuticals, she prefers Biotech’s such as Gilead (GILD-Q) or Celgene (CELG-Q). That is where we are really seeing some of the growth, along with fairly attractive valuations. (See Top Picks.)

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
August 31, 2016

On some of the pharmaceuticals we consistently see some strong volatility, particularly if they lose a trial or their main drugs become generic. Rather than looking at some of these pharmaceuticals, she prefers Biotech’s such as Gilead (GILD-Q) or Celgene (CELG-Q). That is where we are really seeing some of the growth, along with fairly attractive valuations. (See Top Picks.)

Erin Gibbs

Unlock Ratings

Price
$234.540
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
August 22, 2016

(A Top Pick July 11/16. Up 6.4%.) Still one of his biggest holdings. Feels that with the headwinds facing the generics, the branded guys have less of a problem. Trading at a low multiple of about 10-11 times.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
August 22, 2016

(A Top Pick July 11/16. Up 6.4%.) Still one of his biggest holdings. Feels that with the headwinds facing the generics, the branded guys have less of a problem. Trading at a low multiple of about 10-11 times.

PAST TOP PICK
PAST TOP PICK
August 17, 2016

(A Top Pick Sept 22/15. Down 11.98%.) There was pressure early this year because the US Treasury stopped their merger with Pfizer (PFE-N). Feels that Brett Saunders, who runs the company, is a genius allocator. He has created more value than just about any other pharmaceutical company in existence. This is a screaming Buy here.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
August 17, 2016

(A Top Pick Sept 22/15. Down 11.98%.) There was pressure early this year because the US Treasury stopped their merger with Pfizer (PFE-N). Feels that Brett Saunders, who runs the company, is a genius allocator. He has created more value than just about any other pharmaceutical company in existence. This is a screaming Buy here.

TOP PICK
TOP PICK
August 17, 2016

He sees this going into the mid $300 within 12-15 months. They are going to do some deals and they have a fantastic CEO. You don’t know where it is going to be until they do a deal and the earnings accrete. You can be very surprised how fast earnings can accrete when the right deals are done.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
August 17, 2016

He sees this going into the mid $300 within 12-15 months. They are going to do some deals and they have a fantastic CEO. You don’t know where it is going to be until they do a deal and the earnings accrete. You can be very surprised how fast earnings can accrete when the right deals are done.

TOP PICK
TOP PICK
July 11, 2016

There is a catalyst coming any day now. Selling their generics business to Teva Pharmaceutical (TEVA-Q) for $40 billion. $10 billion for buyback, $10 billion to pay down debt and the rest to do some smaller acquisitions. The sentiment around specialty pharmaceuticals has been terrible, so you have a low valuation on a company that should be able to grow their bottom line by double digits.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
July 11, 2016

There is a catalyst coming any day now. Selling their generics business to Teva Pharmaceutical (TEVA-Q) for $40 billion. $10 billion for buyback, $10 billion to pay down debt and the rest to do some smaller acquisitions. The sentiment around specialty pharmaceuticals has been terrible, so you have a low valuation on a company that should be able to grow their bottom line by double digits.

PAST TOP PICK
PAST TOP PICK
June 13, 2016

(A Top Pick July 10/15. Down 21.97%.) As a company, this is one of the better healthcare names, and he thinks it is a very strong name. Unfortunately, healthcare has been under a lot of pressure. Sold his holdings.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
June 13, 2016

(A Top Pick July 10/15. Down 21.97%.) As a company, this is one of the better healthcare names, and he thinks it is a very strong name. Unfortunately, healthcare has been under a lot of pressure. Sold his holdings.

PAST TOP PICK
PAST TOP PICK
April 26, 2016

(A Top Pick May 6/15. Down 22.37%.) Overall a great company, but there has been a lot of pressure on healthcare for some time. He still holds a very small amount. As a shareholder, you will see money coming back to you. They have a very attractive suite of products.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
April 26, 2016

(A Top Pick May 6/15. Down 22.37%.) Overall a great company, but there has been a lot of pressure on healthcare for some time. He still holds a very small amount. As a shareholder, you will see money coming back to you. They have a very attractive suite of products.

HOLD
HOLD
April 19, 2016

Thinks there will be continued M&A in that space. They have a nice product portfolio, so they are still likely out there as a possible acquisition.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
April 19, 2016

Thinks there will be continued M&A in that space. They have a nice product portfolio, so they are still likely out there as a possible acquisition.

COMMENT
COMMENT
April 18, 2016

The ‘hammer’ on candle sticks could be a change of trend. It is hitting an old support level and made a couple of lower highs.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
April 18, 2016

The ‘hammer’ on candle sticks could be a change of trend. It is hitting an old support level and made a couple of lower highs.

DON'T BUY
DON'T BUY
April 14, 2016

Was going to team up with PFE-N, but were stopped with regulatory intervention. He thinks it is going to $200 easy. The balance sheet is too huge now.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
April 14, 2016

Was going to team up with PFE-N, but were stopped with regulatory intervention. He thinks it is going to $200 easy. The balance sheet is too huge now.

COMMENT
COMMENT
March 21, 2016

A great company in the pharmaceutical and healthcare space. The whole space has come down a fair bit because of the big run up we have had for the past 5 years. Also, it is going through a big consolidation phase. He has a cautious view on healthcare because of the run-up with a lot of that being due to the M&A activity. He owns much more value oriented companies such as Boston Scientific (BSX-N) which has not had the run-up that the biotechs and pharmaceuticals have had.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
March 21, 2016

A great company in the pharmaceutical and healthcare space. The whole space has come down a fair bit because of the big run up we have had for the past 5 years. Also, it is going through a big consolidation phase. He has a cautious view on healthcare because of the run-up with a lot of that being due to the M&A activity. He owns much more value oriented companies such as Boston Scientific (BSX-N) which has not had the run-up that the biotechs and pharmaceuticals have had.

DON'T BUY
DON'T BUY
February 17, 2016

Merging with Pfizer (PFE-N), a tax inversion play where Pfizer wants to get offshore to avoid higher US taxes. They are not in the good books of the US legislators, which is a risk. Because of this, he would probably stay clear.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
February 17, 2016

Merging with Pfizer (PFE-N), a tax inversion play where Pfizer wants to get offshore to avoid higher US taxes. They are not in the good books of the US legislators, which is a risk. Because of this, he would probably stay clear.

TOP PICK
TOP PICK
December 10, 2015

It will take 6-8 months for them to merge with PFE-N. You have to understand PFE-N. Before the deal, PFE-N was trading in the $35 range and then dropped to $30 on rumours of the deal. There is a double digit percentage discount to the price of the deal. Post- the merger, by 2018, it will be 10% accretive to all metrics.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
December 10, 2015

It will take 6-8 months for them to merge with PFE-N. You have to understand PFE-N. Before the deal, PFE-N was trading in the $35 range and then dropped to $30 on rumours of the deal. There is a double digit percentage discount to the price of the deal. Post- the merger, by 2018, it will be 10% accretive to all metrics.

BUY
BUY
November 2, 2015

Healthcare has been a favourite of his over the last couple of years. He got stopped out over the last 6 weeks. The government’s focus on drug prices has been a problem. It’s a great business and has come back very nicely. He figures it will get taken out at some point at a higher price.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
November 2, 2015

Healthcare has been a favourite of his over the last couple of years. He got stopped out over the last 6 weeks. The government’s focus on drug prices has been a problem. It’s a great business and has come back very nicely. He figures it will get taken out at some point at a higher price.

TOP PICK
TOP PICK
September 22, 2015

Pharmaceuticals. A growing company from both a drug standpoint and a pipeline standpoint of what they can bring to market. It has a very brilliant CEO who engages in value creating capital allocation. Made a lot of press recently when they sold their generics business to Teva (TEVA-N). The company is known to do very smart transactions in both Buying and Selling. Trading at about 16.5-17 times earnings, but he thinks it is growing 3 or 4 times the growth rate of the market.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
September 22, 2015

Pharmaceuticals. A growing company from both a drug standpoint and a pipeline standpoint of what they can bring to market. It has a very brilliant CEO who engages in value creating capital allocation. Made a lot of press recently when they sold their generics business to Teva (TEVA-N). The company is known to do very smart transactions in both Buying and Selling. Trading at about 16.5-17 times earnings, but he thinks it is growing 3 or 4 times the growth rate of the market.

TOP PICK
TOP PICK
July 10, 2015

A specialty pharma company, and is now #3 in terms of size in North America. It is a tax inversion story and is headquartered in Dublin Ireland. Transformed itself by 2 huge acquisitions. Very fast growth with the top line growing at about 11% per year and bottom line growing at almost 20% a year. Trading at a 16.2X forward earnings multiple and a PEG ratio of about .91. Very, very reasonably priced.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
July 10, 2015

A specialty pharma company, and is now #3 in terms of size in North America. It is a tax inversion story and is headquartered in Dublin Ireland. Transformed itself by 2 huge acquisitions. Very fast growth with the top line growing at about 11% per year and bottom line growing at almost 20% a year. Trading at a 16.2X forward earnings multiple and a PEG ratio of about .91. Very, very reasonably priced.

TOP PICK
TOP PICK
May 6, 2015

Likes the Allergan deal and thinks that once it is fully integrated you will see a drop to the bottom line. The stock should grow its top line by 10%, bottom line by 15%-20%. This is the #3 generic pharmaceutical company in the US. They also do some branded stuff. This is really a play on healthcare and aging demographics. A very strong grower and one of the ones that has really been kind of overlooked in what was a very strong run up in health care. Hasn’t performed to the extent that it could. A solid core business and has tremendous upside.

Show full opinionHide full opinion

Likes the Allergan deal and thinks that once it is fully integrated you will see a drop to the bottom line. The stock should grow its top line by 10%, bottom line by 15%-20%. This is the #3 generic pharmaceutical company in the US. They also do some branded stuff. This is really a play on healthcare and aging demographics. A very strong grower and one of the ones that has really been kind of overlooked in what was a very strong run up in health care. Hasn’t performed to the extent that it could. A solid core business and has tremendous upside.

COMMENT
COMMENT
April 21, 2015

Pharmaceutical sector is really attractive. The industry has moved from more science based to more distribution business model based. This company has made a business of making acquisitions, tucking them in, cutting costs and then using their distribution power to basically put more apples on the applecart when they go out to sell their product. They have done it successfully time and time again. Looks very attractive.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
April 21, 2015

Pharmaceutical sector is really attractive. The industry has moved from more science based to more distribution business model based. This company has made a business of making acquisitions, tucking them in, cutting costs and then using their distribution power to basically put more apples on the applecart when they go out to sell their product. They have done it successfully time and time again. Looks very attractive.

WATCH
WATCH
February 19, 2014

Acquisition of Forest Labs is definitely a positive for them. Have excellent prospects in their R&D groundbreaking drugs. On a PE basis, the multiple is always insane, however the key thing to look for is the PEG ratio. When this is under 1 that is an opportunity to purchase.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
February 19, 2014

Acquisition of Forest Labs is definitely a positive for them. Have excellent prospects in their R&D groundbreaking drugs. On a PE basis, the multiple is always insane, however the key thing to look for is the PEG ratio. When this is under 1 that is an opportunity to purchase.

TOP PICK
TOP PICK
February 25, 2013

(Top Pick Jul 6/12, Up 13.17%) A problem with them not hitting a settlement. Next product in a little while. 28 times earnings. Growth is so high that it will be less than 10. Second largest generic drug company in the world. TEVA has a whole lot of warts on it at this point.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
February 25, 2013

(Top Pick Jul 6/12, Up 13.17%) A problem with them not hitting a settlement. Next product in a little while. 28 times earnings. Growth is so high that it will be less than 10. Second largest generic drug company in the world. TEVA has a whole lot of warts on it at this point.

PAST TOP PICK
PAST TOP PICK
November 30, 2012

(Top Pick July 6/11, Up 15.96%)

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
November 30, 2012

(Top Pick July 6/11, Up 15.96%)

TOP PICK
TOP PICK
August 24, 2012

Recently bought a company in Europe, largest producer of a generic drug for ADD. It is highly accretive and analysts have been slow to raise their earnings estimates. Executed nicely and have close to 30% market share in generic Lipitor.

Show full opinionHide full opinion
Allergan PLC. (AGN-N)
August 24, 2012

Recently bought a company in Europe, largest producer of a generic drug for ADD. It is highly accretive and analysts have been slow to raise their earnings estimates. Executed nicely and have close to 30% market share in generic Lipitor.